Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting
- Author(s)
- Madariaga, A; Veneziani, A; Bookman, M; Counsell, N; Miller, A; Andrews, J; Banerjee, S; Chavez-Blanco, A; Cloven, N; Gaba, F; Kohn, E; Leary, A; Lecuru, F; Lee, YC; Lee, JY; Liu, Y; Lindemann, K; Malik, S; Marth, C; Mileshkin, L; Mukhopadhyay, A; Nadeem, A; Nout, R; Pérez-Fidalgo, JA; Plante, M; Sundar, S; Tone, A; Oza, AM; Glasspool, R; Mackay, H;
- Details
- Publication Year 2026-06-23,Volume 36,Issue #9,Page 104827
- Journal Title
- International Journal of Gynecological Cancer
- Publication Type
- Review
- Abstract
- Randomized controlled trials remain fundamental to evidence generation in oncology but are increasingly complex, costly, and often misaligned with real-world practice. Traditional explanatory trials, designed under ideal, controlled conditions, frequently enroll highly selected populations, limiting generalizability and underrepresenting key groups such as older adults, patients with comorbidities, and those from low- and middle-income countries. Pragmatic clinical trials offer an alternative by evaluating interventions under routine care conditions, with broader eligibility, simplified procedures, and patient-centered outcomes. To address these challenges, the Gynecologic Cancer InterGroup convened an international brainstorming meeting in May 2025 with multi-disciplinary experts, patients, and advocates to define priorities and develop a roadmap for pragmatic trials in gynecologic oncology. Key discussions emphasized embedding trial design within routine care, aligning eligibility criteria and procedures with standard practice, minimizing non-essential data collection, and prioritizing outcomes meaningful to patients, including quality of life. Innovative designs such as registry-based randomized trials, trials-within-cohorts, and cluster randomization were highlighted as feasible approaches to improve efficiency while preserving internal validity. Integration of patient-reported outcomes and real-world data was considered achievable when carefully streamlined. Major challenges identified included regulatory heterogeneity, consent complexity, data interoperability, and funding limitations, particularly in multi-national settings. Proposed solutions include simplified consent models, centralized ethics processes, hybrid funding strategies, and the responsible use of artificial intelligence to enhance patient identification, recruitment, and potential development of synthetic control arms. Patient engagement was recognized as essential to ensure relevance, feasibility, and equity. Incorporation of patient-reported outcomes was discussed as key to informing acceptance and tolerability. In summary, pragmatic trials within Gynecologic Cancer InterGroup represent a critical pathway to generate efficient, inclusive, and practice-changing evidence in gynecologic cancers across diverse health care settings.
- Publisher
- Elsevier
- Keywords
- Global Oncology; Gynecologic Oncology; Patient-Reported Outcomes; Pragmatic Clinical Trials; Real-World Evidence
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.ijgc.2026.104827
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-08-11 05:52:47
Last Modified: 2026-08-11 05:53:16